Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
F Kasteng, M Erlanson, H Hagberg, E Kimby… - Acta …, 2008 - Taylor & Francis
Introduction. Rituximab has significantly improved the prognosis for patients with both
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
F Kasteng, M Erlanson, H Hagberg… - Acta Oncologica …, 2008 - europepmc.org
Materials and methods The incremental cost and effectiveness of rituximab maintenance
therapy versus observation were evaluated in a health-state transition model. Primary effect …
therapy versus observation were evaluated in a health-state transition model. Primary effect …
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
F Kasteng, M Erlanson, H Hagberg, E Kimby… - Acta …, 2008 - diva-portal.org
INTRODUCTION: Rituximab has significantly improved the prognosis for patients with both
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
[PDF][PDF] Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
F KASTENG, M ERLANSON, H HAGBERG… - Acta …, 2008 - researchgate.net
Introduction. Rituximab has significantly improved the prognosis for patients with both
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
F Kasteng, M Erlanson, H Hagberg, E Kimby… - Acta …, 2008 - actaorthop.org
Introduction. Rituximab has significantly improved the prognosis for patients with both
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
F Kasteng, M Erlanson, H Hagberg, E Kimby… - Acta …, 2008 - portal.research.lu.se
Introduction. Rituximab has significantly improved the prognosis for patients with both
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
F Kasteng, M Erlanson, H Hagberg, E Kimby… - Acta …, 2008 - search.ebscohost.com
Introduction. Rituximab has significantly improved the prognosis for patients with both
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
[引用][C] Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
F Kasteng, M Erlanson, H Hagberg, E Kimby… - Acta Oncologica - lunduniversity.lu.se
Introduction. Rituximab has significantly improved the prognosis for patients with both
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
F Kasteng, M Erlanson, H Hagberg, E Kimby… - Acta Oncologica, 2008 - lup.lub.lu.se
Introduction. Rituximab has significantly improved the prognosis for patients with both
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
F Kasteng, M Erlanson, H Hagberg, E Kimby… - 2008 - pubmed.ncbi.nlm.nih.gov
Introduction Rituximab has significantly improved the prognosis for patients with both
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …